Research-Grade Exosome Production
OverviewServicesSamplesAdvantagesApplicationsCase StudyFAQs
Overview
Reproducibility in extracellular vesicle research hinges on a single, deceptively simple variable: the quality and consistency of the vesicle preparation itself. When batch-to-batch variation in particle size, purity, or bioactivity obscures experimental signals, even the most carefully designed study can produce ambiguous results. Creative BioMart Microbe addresses this foundational challenge with a research-grade microbial extracellular vesicle (mEV) production service built around small-batch flexibility, transparent documentation, and the characterization depth that peer reviewers and grant committees now expect.
Our platform spans Gram-negative outer membrane vesicles, Gram-positive cytoplasmic membrane vesicles, fungal extracellular vesicles, and phage-derived vesicles. For each project, we tailor fermentation scale (shake-flask through bench-top bioreactor), isolation method (ultracentrifugation, density gradient, tangential flow filtration, or polymer precipitation), and characterization depth to the specific research question. Every batch ships with raw data files, summary reports, and a Certificate of Analysis formatted for electronic lab notebooks and manuscript supplementary materials. Projects that begin at research grade can transition through our tiered compliance pathway—Food-Grade, Cosmetic-Grade, and GMP-Grade—without redundant revalidation. For project-specific requirements or to discuss experimental design, contact us.
Figure 1. Schematic overview of the research-grade microbial extracellular vesicle production platform, integrating strain qualification, flexible-batch fermentation, multi-method isolation, physicochemical and biochemical characterization, and complete research data packaging into a single, transparent workflow.
Services
Service Workflow
Our research-grade mEV production flow organizes every project into three coordinated stages: configure (strain intake, culture design, and characterization scope), produce (fermentation, isolation, and purification), and qualify (physicochemical analysis, biochemical profiling, and documentation). Parallel-track options support method-comparison and parameter-optimization studies within a single project timeline.
Service Details
Strain Selection & Fermentation Development
We produce mEVs from client-provided strains or source standard isolates from ATCC and DSMZ collections. Culture runs span shake-flask volumes (10–500 mL) to bench-top bioreactor batches (0.5–5 L) with real-time pH, dissolved oxygen, and temperature monitoring. Parallel condition screening supports rapid optimization of medium composition and harvest timing for maximum vesicle yield.
Custom Strain Engineering for Enhanced EV Secretion
We construct hypervesiculating strains through targeted gene deletion (mlaE, nlpI, tolR) and engineered expression of recombinant cargo proteins. Fluorescent reporter fusions enable real-time tracking of EV production and cargo loading efficiency. Each engineered strain is verified by sequencing and growth characterization before entering the production workflow.
Multi-Method Isolation & Purification
A single culture can be split across multiple isolation methods—differential ultracentrifugation, iodixanol or sucrose density gradient, tangential flow filtration, or polymer-based precipitation. We report vesicle recovery efficiency, protein carryover, and post-isolation bioactivity for each method, enabling evidence-based protocol selection for downstream applications.
Comprehensive Physicochemical Characterization
Every batch undergoes particle concentration and size analysis by nanoparticle tracking, morphology verification by transmission electron microscopy, hydrodynamic diameter by dynamic light scattering, and surface charge by zeta potential measurement. Optional upgrades include cryo-TEM, atomic force microscopy, and nanoparticle flow cytometry for single-particle multiparametric analysis.
Biochemical Marker & Composition Analysis
We confirm vesicle identity through quantitative detection of source-specific markers: outer membrane proteins for Gram-negative OMVs, lipoteichoic acid for Gram-positive CMVs, and β-glucan for fungal EVs. Total protein and lipid assays, endotoxin quantification, and optional mass-spectrometry-based proteomic and lipidomic profiling provide publication-grade compositional data.
Research Data Package & Batch Documentation
Deliverables include a Certificate of Analysis summarizing all quality attributes, complete production records, raw and processed characterization data, biochemical profiling results, and stability monitoring reports. Files are organized in standardized formats compatible with electronic lab notebooks, manuscript supplementary materials, and IND-enabling CMC sections.
Service Specifications & QC Standards
Instrumentation & Analytical Capability
- Nanoparticle Tracking Analysis: Multi-laser systems for particle concentration (107–1012 particles/mL) and size distribution (50–1000 nm).
- Transmission Electron Microscopy: Negative-stain and cryo-TEM platforms for vesicle morphology and structural integrity.
- Dynamic Light Scattering: Multi-angle systems for hydrodynamic diameter and polydispersity index determination.
- Electrophoretic Light Scattering: Zeta potential analyzers for surface charge and colloidal stability assessment.
- Biochemical Analysis: Multi-mode microplate readers, capillary electrophoresis, and mass spectrometry platforms for protein, lipid, and nucleic acid profiling.
- Ultracentrifugation: Fixed-angle and swinging-bucket rotors covering differential and density-gradient separation protocols.
- Tangential Flow Filtration: Hollow-fiber and cassette-based systems for scalable concentration and diafiltration.
- Fermentation Systems: Shake-flask incubators and bench-top bioreactors (0.5–5 L) with real-time process monitoring.
Production & Characterization Specifications
| Parameter |
Specification |
| Batch Volume Range |
10 mL – 5 L culture volume |
| Vesicle Yield |
1011–1014 particles per batch (strain-dependent); engineered hypervesiculating strains available for yield enhancement |
| Mean Diameter |
20–300 nm (source-dependent) |
| Purity Metrics |
Protein/particle ratio reported; low-protein or high-activity options available |
| Endotoxin Level |
Reported per batch; low-endotoxin options available |
| Characterization Depth |
Tier 1 (NTA + TEM + DLS + zeta), Tier 2 (add biochemical markers), Tier 3 (add proteomics/lipidomics) |
| Turnaround Time |
2–6 weeks depending on batch scale and characterization tier |
| Storage Buffer |
PBS, Tris, or custom formulation; cryoprotectant options available |
| Storage Temperature |
−80°C (standard); −20°C or 4°C short-term upon request |
| Data Package |
Certificate of Analysis, raw data files, summary reports, batch production records |
Samples
We accept client-provided microbial strains or source standard strains from public culture collections. Complete strain documentation enables accurate production and full experimental traceability.
| Sample Type |
Requirements |
Shipping Conditions |
| Client-Provided Bacterial Strains |
Glycerol stock (≥15% v/v) or agar stab; ≥1 mL; clearly labeled with strain name and genotype; biosafety level indicated |
Dry ice or cold pack; overnight shipping |
| Client-Provided Fungal Strains |
Active culture on agar slant or spore suspension; ≥1 mL; species identification confirmed |
Ambient or cold pack; express shipping |
| Engineered Strains |
Glycerol stock with antibiotic resistance markers specified; plasmid map or genotype documentation required; construct stability data appreciated |
Dry ice; overnight shipping |
| Standard Reference Strains |
Sourced from ATCC, DSMZ, or JCM collections; lead time 1–2 weeks |
N/A (sourced internally) |
| Phage Lysates |
High-titer lysate (≥109 PFU/mL); ≥1 mL; host strain specified |
Dry ice; overnight shipping |
Advantages
- No Minimum Order Volume — Projects start at 10 mL shake-flask culture, with batch sizes scalable to 5 L. Researchers pay only for the material they need, not a fixed production minimum.
- Method-Comparison Capability — A single culture can be split across ultracentrifugation, density gradient, TFF, and polymer precipitation in parallel, generating side-by-side purity and bioactivity data that inform downstream protocol decisions.
- Characterization Depth, Not Defaults — Three tiered characterization packages let investigators match analytical depth to project stage: basic physical profiling for pilot experiments, biochemical marker analysis for publication, full multi-omics for mechanistic studies.
- Engineered Strain Expertise — Ready access to hypervesiculating strain construction (mlaE, nlpI, tolR knockouts) and recombinant cargo loading means researchers receive production-optimized strains, not just vesicles.
- Full Traceability by Default — Every batch ships with strain identity verification, growth curves, isolation parameters, characterization raw data, and a Certificate of Analysis—no supplemental documentation requests needed.
- Multi-Source Coverage — Production experience spans Gram-negative OMVs, Gram-positive CMVs, fungal EVs, and phage-derived vesicles, enabling comparative studies across microbial kingdoms on a single platform.
- Publication-Ready Deliverables — Raw data files, statistical summaries, and high-resolution TEM images are structured for direct insertion into manuscript figures and supplementary materials.
- Pathway to Application Tiers — Research-grade projects that show translational promise transition seamlessly to food-grade, cosmetic-grade, or GMP-grade manufacturing with preserved process knowledge and documentation continuity.
Applications
Mechanism-of-Action Research
Reproducible, well-characterized mEVs support fundamental studies of vesicle biogenesis, cargo sorting, host-pathogen signaling, and inter-kingdom communication at the molecular level.
Biomarker & Diagnostic Development
Defined bacterial and fungal EV reference preparations enable assay development for infection diagnostics, biomarker validation, and clinical correlation studies with reproducible positive controls.
Vaccine & Drug Delivery Research
Research-grade OMVs and engineered vesicles serve as natural nanocarrier platforms for antigen presentation, adjuvant screening, and targeted delivery of nucleic acids and small molecules.
Strain Screening & Comparative Studies
Parallel production from multiple strains or engineered variants enables systematic comparison of vesiculation phenotypes, cargo profiles, and bioactivity across strain panels.
Case Study
Case Study 1: Hypervesiculating Strain Construction for Enhanced OMV Yield
The inherently low vesicle yield of wild-type probiotic strains limits both mechanistic research and translational development of outer membrane vesicle (OMV)-based products. Sawabe et al. (2024) addressed this bottleneck by constructing a hypervesiculating derivative of the well-characterized probiotic Escherichia coli Nissle 1917 (EcN) through double deletion of mlaE and nlpI—genes controlling phospholipid retrograde transport and lipoprotein–peptidoglycan crosslinking, respectively. The ΔmlaEΔnlpI double mutant produced approximately 8 times more OMVs than wild-type EcN while retaining the ability to grow under standard culture conditions. Quick-freeze deep-etch electron microscopy revealed that hypervesiculation was driven by extensive peptidoglycan perforation, which created membrane exit sites while preserving sufficient cell wall integrity for sustained culture viability. For research-grade EV production, this study demonstrates that genetic engineering can overcome the yield limitations of probiotic chassis strains without requiring exotic culture additives or specialized equipment—making high-yield OMV production accessible to academic laboratories and early-stage biotech programs operating within standard bench-top infrastructure.
Figure 2. OMV production in EcN wild-type and its gene knockout mutants, with transmission electron micrographs of isolated OMVs showing multilamellar structures in the ΔmlaEΔnlpI double mutant. (Sawabe, et al. 2024)
Case Study 2: BEV Research Practices and Quality Standards
The translational potential of bacterial extracellular vesicles (BEVs) is undermined when published studies lack the characterization depth needed for independent replication. De Langhe et al. (2024) quantified this problem by systematically analyzing 3,338 experiments from 845 BEV publications (2015–2021) using the EV-METRIC transparency framework. Their findings were striking: 29% of experiments reported no biophysical or biochemical characterization whatsoever, only 25% combined both characterization types, and fewer than 3% of density gradient experiments fully documented gradient parameters. The average BEV study achieved an EV-METRIC score of just 14.5%, compared with 28.5% for eukaryotic EV research. Critically, BEV transparency scores plateaued after 2018 while eukaryotic EV scores continued rising—indicating a field-wide gap in adoption of characterization standards. The authors proposed minimum reporting requirements spanning source documentation, preparation parameters, biophysical characterization, and biochemical marker validation that together establish a reproducible quality framework. For research-grade EV production services, this meta-analysis provides an evidence-based blueprint: every batch must deliver the characterization data that the field currently lacks, transforming production from a black-box service into a transparent, publication-ready scientific resource.
Figure 3. BEV research practices across source, preparation, and characterization methods in published literature, showing phylogenetic distribution of studied species and method combination frequencies. (De Langhe, et al. 2024)
FAQs
Q: What defines research-grade mEV production, and how does it differ from other compliance tiers?
A: Research-grade production prioritizes flexibility, speed, and characterization depth for hypothesis-driven studies. It operates in a controlled laboratory environment with full documentation but without formal GMP quality systems. Food-grade production adds contaminant-controlled processing and food-safety testing for human consumption; GMP production implements validated SOPs, aseptic manufacturing, and regulatory audit trails for clinical trials. Research-grade projects that yield promising data can transition through our Food-Grade to GMP-Grade pathway with preserved process history.
Q: Which isolation method should I choose for my research project?
A: The optimal method depends on your downstream application. Ultracentrifugation offers high yield for bulk biochemical assays; density gradient centrifugation provides the highest purity for proteomic or functional studies where contaminating proteins must be minimized; tangential flow filtration preserves vesicle integrity best for cell-based functional assays; polymer-based precipitation enables rapid recovery when speed matters more than purity. We recommend method-comparison runs for novel strains or new research questions—splitting one culture across multiple methods generates the data needed to make an evidence-based choice for subsequent batches.
Q: Can you produce vesicles from genetically engineered or hypervesiculating strains?
A: Yes. We accept client-engineered strains and can construct hypervesiculating mutants through targeted gene deletion (mlaE, nlpI, tolR) or recombinant cargo expression. Published hypervesiculation strategies achieve 8–50-fold yield enhancement over wild-type, depending on the chassis strain and genetic modification. We verify construct stability, growth characteristics, and enhanced vesicle production before entering the full production workflow.
Q: What characterization data is included with each research-grade batch?
A: Every batch includes, at minimum, nanoparticle tracking analysis (concentration and size distribution), transmission electron microscopy (morphology and structural integrity), dynamic light scattering (hydrodynamic diameter and polydispersity), and zeta potential (surface charge stability). Tier 2 adds biochemical marker analysis (OMP, LTA, or β-glucan detection, total protein and lipid quantitation). Tier 3 adds mass-spectrometry-based proteomic and/or lipidomic profiling. All raw data files and processed reports are delivered in standard formats compatible with publication and data archiving requirements.
Q: What is the minimum batch size and how quickly can I receive material?
A: Our minimum batch starts from a 10 mL shake-flask culture, yielding approximately 1011–1012 particles depending on the strain. Standard turnaround is 2–6 weeks, scaled by batch volume and characterization tier. Pilot batches with basic characterization (Tier 1) can be delivered in 2–3 weeks, while larger bioreactor runs with full multi-omics profiling (Tier 3) require 5–6 weeks. Expedited timelines are available for grant deadlines and conference submissions.
Q: Do you support multi-strain comparative studies?
A: Yes. Parallel production from multiple strains—wild-type versus mutant panels, species across Gram-negative and Gram-positive boundaries, or fungal versus bacterial comparisons—is a core capability. We run parallel cultures under identical conditions with matched isolation and characterization protocols, generating directly comparable datasets suitable for publication-grade comparative figures and statistical analysis.
Q: How are research-grade mEVs stored, and what is their shelf life?
A: We ship vesicles in PBS or a custom buffer at −80°C with cryoprotectant options available for freeze-thaw-sensitive preparations. Typical shelf life is 6–12 months at −80°C, with stability monitoring data provided for each batch. Short-term storage at −20°C (up to 1 month) or 4°C (up to 1 week) is possible depending on vesicle source. We advise against repeated freeze-thaw cycles and provide aliquot recommendations based on your planned experimental schedule.
Q: What strain documentation and biosafety information do I need to provide?
A: For client-provided strains, we require species name, genotype or phenotype description, culture medium preferences, biosafety level, and any relevant antibiotic resistance markers. 16S rRNA or ITS sequence confirmation, growth curve data, and prior vesicle yield estimates are appreciated but not mandatory. Proprietary strains are handled under confidentiality agreements, and material transfer agreements are available when needed.
References:
- Sawabe, T., et al. (2024). Construction and characterization of a hypervesiculation strain of Escherichia coli Nissle 1917. PLOS ONE, 19(4), e0301613.
- De Langhe, N., et al. (2024). Mapping bacterial extracellular vesicle research: insights, best practices and knowledge gaps. Nature Communications, 15, 9410.
